Pam M. Van Ry, Ph.D.
Affiliations: | 2014 | Cell and Molecular Pharmacology and Physiology | University of Nevada, Reno, Reno, NV, United States |
Area:
Molecular Biology, PharmacologyGoogle:
"Pam Van Ry"Mean distance: 30533.1
Parents
Sign in to add mentor| Dean J. Burkin | grad student | 2014 | University of Nevada, Reno | |
| (Protein Therapy for Muscular Dystrophy and Other Muscle Diseases.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Vallecillo-Zúniga ML, Rathgeber M, Poulson D, et al. (2022) Evaluating Therapeutic Activity of Galectin-1 in Sarcolemma Repair of Skeletal Muscle. Methods in Molecular Biology (Clifton, N.J.). 2442: 663-683 |
| Vallecillo-Zúniga ML, Poulson PD, Luddington JS, et al. (2021) Therapeutic Benefit of Galectin-1: Beyond Membrane Repair, a Multifaceted Approach to LGMD2B. Cells. 10 |
| Vallecillo-Zúniga ML, Rathgeber MF, Poulson PD, et al. (2020) Treatment with galectin-1 improves myogenic potential and membrane repair in dysferlin-deficient models. Plos One. 15: e0238441 |
| Wuebbles RD, Cruz V, Van Ry P, et al. (2019) Human Galectin-1 Improves Sarcolemma Stability and Muscle Vascularization in the mdx Mouse Model of Duchenne Muscular Dystrophy. Molecular Therapy. Methods & Clinical Development. 13: 145-153 |
| Van Ry PM, Fontelonga TM, Barraza-Flores P, et al. (2017) ECM-Related Myopathies and Muscular Dystrophies: Pros and Cons of Protein Therapies. Comprehensive Physiology. 7: 1519-1536 |
| Willmann R, Gordish-Dressman H, Meinen S, et al. (2017) Improving Reproducibility of Phenotypic Assessments in the DyW Mouse Model of Laminin-α2 Related Congenital Muscular Dystrophy. Journal of Neuromuscular Diseases |
| Lewon M, Peters CM, Van Ry PM, et al. (2017) Evaluation of the behavioral characteristics of the mdx mouse model of duchenne muscular dystrophy through operant conditioning procedures. Behavioural Processes. 142: 8-20 |
| Doe J, Kaindl AM, Jijiwa M, et al. (2017) PTRH2 gene mutation causes progressive congenital skeletal muscle pathology. Human Molecular Genetics |
| Van Ry PM, Wuebbles RD, Key M, et al. (2015) Galectin-1 Protein Therapy Prevents Pathology and Improves Muscle Function in the mdx Mouse Model of Duchenne Muscular Dystrophy. Molecular Therapy : the Journal of the American Society of Gene Therapy. 23: 1285-97 |
| Griffiths GS, Doe J, Jijiwa M, et al. (2015) Bit-1 is an essential regulator of myogenic differentiation. Journal of Cell Science. 128: 1707-17 |